CN108349966B - 1,3,4-噻二唑化合物及其在治疗癌症中的用途 - Google Patents

1,3,4-噻二唑化合物及其在治疗癌症中的用途 Download PDF

Info

Publication number
CN108349966B
CN108349966B CN201680067245.3A CN201680067245A CN108349966B CN 108349966 B CN108349966 B CN 108349966B CN 201680067245 A CN201680067245 A CN 201680067245A CN 108349966 B CN108349966 B CN 108349966B
Authority
CN
China
Prior art keywords
methoxy
phenyl
thiadiazol
acetamide
pyridazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680067245.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108349966A (zh
Inventor
M.R.V.芬莱
J.W.M.尼辛克
M.D.查尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
AstraZeneca AB
Original Assignee
Cancer Research Technology Ltd
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd, AstraZeneca AB filed Critical Cancer Research Technology Ltd
Publication of CN108349966A publication Critical patent/CN108349966A/zh
Application granted granted Critical
Publication of CN108349966B publication Critical patent/CN108349966B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680067245.3A 2015-11-30 2016-11-30 1,3,4-噻二唑化合物及其在治疗癌症中的用途 Active CN108349966B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562260789P 2015-11-30 2015-11-30
US62/260789 2015-11-30
PCT/EP2016/079250 WO2017093299A1 (en) 2015-11-30 2016-11-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (2)

Publication Number Publication Date
CN108349966A CN108349966A (zh) 2018-07-31
CN108349966B true CN108349966B (zh) 2022-02-15

Family

ID=57485461

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680067245.3A Active CN108349966B (zh) 2015-11-30 2016-11-30 1,3,4-噻二唑化合物及其在治疗癌症中的用途

Country Status (24)

Country Link
US (3) US10323028B2 (cg-RX-API-DMAC7.html)
EP (1) EP3383873B1 (cg-RX-API-DMAC7.html)
JP (1) JP6999550B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180083942A (cg-RX-API-DMAC7.html)
CN (1) CN108349966B (cg-RX-API-DMAC7.html)
AR (1) AR106874A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016363718B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018010806A2 (cg-RX-API-DMAC7.html)
CA (1) CA3005495C (cg-RX-API-DMAC7.html)
CL (1) CL2018001407A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018006928A2 (cg-RX-API-DMAC7.html)
EA (1) EA201891241A1 (cg-RX-API-DMAC7.html)
ES (1) ES2914333T3 (cg-RX-API-DMAC7.html)
IL (1) IL259510A (cg-RX-API-DMAC7.html)
MX (1) MX2018006532A (cg-RX-API-DMAC7.html)
NI (1) NI201800064A (cg-RX-API-DMAC7.html)
PE (1) PE20181565A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501131A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018123714A (cg-RX-API-DMAC7.html)
SG (1) SG11201803810XA (cg-RX-API-DMAC7.html)
SV (1) SV2018005702A (cg-RX-API-DMAC7.html)
TN (1) TN2018000127A1 (cg-RX-API-DMAC7.html)
TW (1) TW201733587A (cg-RX-API-DMAC7.html)
WO (1) WO2017093299A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN110741003B (zh) * 2017-06-13 2021-07-23 南京明德新药研发有限公司 作为gls1抑制剂的化合物
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
WO2025196446A1 (en) * 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115698A1 (en) * 2000-08-10 2002-08-22 Newcomb Robert W. Selective inhibition of glutaminase by bis-thiadiazoles
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN105051041A (zh) * 2012-11-16 2015-11-11 卡利泰拉生物科技公司 杂环谷氨酰胺酶抑制剂
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
KR20160100407A (ko) 2014-01-06 2016-08-23 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제의 저해제
GB201520959D0 (en) 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201731511A (zh) 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US10323028B2 (en) 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115698A1 (en) * 2000-08-10 2002-08-22 Newcomb Robert W. Selective inhibition of glutaminase by bis-thiadiazoles
CN105051041A (zh) * 2012-11-16 2015-11-11 卡利泰拉生物科技公司 杂环谷氨酰胺酶抑制剂
WO2015138902A1 (en) * 2014-03-14 2015-09-17 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2015181539A1 (en) * 2014-05-30 2015-12-03 Astrazeneca Ab 1, 3, 4-thiadiazole compounds and their use in treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors;Krupa Shukla et al.;《Journal of Medicinal Chemistry》;20121114;第55卷;第10551-10563页 *

Also Published As

Publication number Publication date
US11753405B2 (en) 2023-09-12
SG11201803810XA (en) 2018-06-28
CL2018001407A1 (es) 2018-10-12
MX2018006532A (es) 2019-05-15
US20170152255A1 (en) 2017-06-01
JP2018535986A (ja) 2018-12-06
PE20181565A1 (es) 2018-10-03
WO2017093299A1 (en) 2017-06-08
CN108349966A (zh) 2018-07-31
BR112018010806A2 (en) 2018-11-27
CA3005495A1 (en) 2017-06-08
EP3383873A1 (en) 2018-10-10
AU2016363718B2 (en) 2019-11-14
CA3005495C (en) 2023-12-12
SV2018005702A (es) 2018-11-27
US10323028B2 (en) 2019-06-18
PH12018501131A1 (en) 2019-01-21
AU2016363718A1 (en) 2018-07-12
US20210246131A1 (en) 2021-08-12
NI201800064A (es) 2018-10-18
JP6999550B2 (ja) 2022-02-10
ES2914333T3 (es) 2022-06-09
TN2018000127A1 (en) 2019-10-04
TW201733587A (zh) 2017-10-01
RU2018123714A (ru) 2020-01-09
US10981904B2 (en) 2021-04-20
IL259510A (en) 2018-07-31
CO2018006928A2 (es) 2018-10-10
EA201891241A1 (ru) 2019-01-31
KR20180083942A (ko) 2018-07-23
AR106874A1 (es) 2018-02-28
US20190389853A1 (en) 2019-12-26
EP3383873B1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
EP3917527B1 (en) Compounds and uses thereof
US11753405B2 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
CN106795150B (zh) 1,3,4-噻二唑化合物及其在治疗癌症中的用途
CN108349965B (zh) 1,3,4-噻二唑化合物及其在治疗癌症中的用途
CN101754966A (zh) 丙型肝炎病毒抑制剂
CN108349967B (zh) 1,3,4-噻二唑化合物及其在治疗癌症中的用途
US10577354B2 (en) Bis-pyridazine compounds and their use in treating cancer
HK1260708B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260708A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
HK1260702B (en) 1,3,4-thiadiazole compounds and their use in treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant